

Hasan Tahir

**BSc, MB BS, MSc (Sports Ex-Med), MFSEM (UK), FRCPE, FRCP (UK)
CCST General (Internal) Medicine & Rheumatology**

Consultant Physician & Rheumatologist

Hon. Professor in Clinical Sciences (St Mathews University)

**Hon. Reader in Investigational Clinical Rheumatology
(Queen Mary University London)**

**Hon. Professor of Clinical Medicine & London Dean
(New Vision University, School of Medicine)**



Curriculum Vita

Personal Details

Name **Hasan TAHIR**
Work Address Royal Free London NHS Foundation Trust, Barnet Hospital, LONDON
Contacts Secretary: 02071234596 E-Mail hasan.tahir@nhs.net
GMC Registration Full - Number 4332044

Education

1983 - 1990 City of London School, Queen Victoria Street, London
1990 - 1996 King's College School of Medicine and Dentistry
University of London
2007 - 2012 University of Bath

Qualifications

1993 B.Sc. **First Class Honours** in
Basic Medical Science with Pharmacology
1996 MB BS
1999 MRCP (UK)
2009 FRCP (UK)
2012 MSc Sports & Exercise Medicine
2019 FRCPE

Awards & Prizes

1993 **Medical Research Council Scholarship**
1995 Commonwealth Foundation Medical Bursary
1996 MDU Medical Elective Bursary
1996 Medicine Group Fellowship Award
1996 Glaxo Medical Fellowship Award
1996 Mary Swann Prize in Obstetrics and Gynaecology
1996 Pharmacia Clinical Medicine Award
2004 BSR UK Travelling Fellowship
Abbott Immunology Travel Bursary
2010 Wyeth Medical education Grant (200K)
2011 Abbott Research Grant (24K)
2013 Roche Education Grant (19K)
2014 Pfizer medical education grant (20K)
2016 Barts Health Innovation award 2016
BSR Best Practice award for Best emerging practice
NIHR@10 PI research award – awarded to only 5 researchers nationally
NIHR “consistently delivers to target” award 2106
2018 Barts Health Innovation Award for Biologics Virtual Clinic

Hospital Appointments

Nov. 2019- Current	<u>Consultant Physician & Rheumatologist</u> ROYAL FREE LONDON NHS FOUNDATION TRUST, BARNET HOSPITAL, LONDON
Feb. 2005 – November 2019	Consultant Physician in Rheumatology & Acute Medicine Clinical & Research Lead for Rheumatology Programme Director for overseas medical students BARTS HEALTH NHS TRUST, LONDON
Dec. 1999 – Feb 2005	SpR Rheumatology & General Medicine NORTH THAMES DEANERY
Aug. 1997 - Dec. 1999	SHO Renal Medicine & High Dependency Unit GUYS & ST THOMAS' HOSPITAL, LONDON SHO Medical Rotation NORTHWICK PARK HOSPITAL, LONDON
Aug. 1996 - Aug. 1997	House Surgeon & House Physician, Professorial Medical Unit KING'S COLLEGE HOSPITAL, LONDON

Academic Post

2019-	Hon. Professor of Clinical Medicine & London Dean New Vision University, School of Medicine
2019-	Associate UK Dean St Matthews University School of Medicine
2017-	Hon. Reader in Investigational Clinical Rheumatology William Harvey Research Institute, Barts and The London, Queen Mary's School of Medicine and Dentistry, London
2015-	Hon. Professor of Clinical Medicine University of Medicine & Health Sciences
2012 -17	Hon. Senior Lecturer in Investigational Clinical Rheumatology William Harvey Research Institute, Barts and The London, Queen Mary's School of Medicine and Dentistry, London
2009-	Hon. Professor of Clinical Sciences St Matthews University School of Medicine

Other Work

Aug. 2006 – Jan 2009	Healthcare Commission Complaints Advisor
Jan 2006 – 2010	TV presenter – Health Show – Sky 813

Membership of Professional Associations

British Society for Rheumatology
Royal College of Physicians, London
Royal College of Physicians, Edinburgh
British Medical Association
Faculty of Sports & Exercise Medicine
Brit SpA
Member of ASAS

Sample of Publications (in the last 2 years)

1. van der Heijde D, Mease PJ, Landewé RBM, Rahman P, **Tahir H**, Singhal A, Boettcher E, Navarra S, Zhu X, Ligozio G, Readie A, Mpofu S, Pricop L. Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5. *Rheumatology (Oxford)*. 2019 Oct 5. pii: kez420. doi: 10.1093/rheumatology
2. Baraliakos X, Braun J, Deodhar A, Poddubnyy D, Kivitz A, **Tahir H**, Van den Bosch F, Delicha EM, Talloczy Z, Fierlinger A. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. *RMD Open*. 2019 Sep 3;5(2): doi: 10.1136/rmdopen-2019-001005.
3. Mease PJ, Smolen JS, Behrens F, Nash P, Liu Leage S, Li L, **Tahir H**, Gooderham M, Krishnan E, Liu-Seifert H, Emery P, Pillai SG, Helliwell PS; SPIRIT H2H study group. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. *Ann Rheum Dis*. 2019 Sep 28. pii: annrheumdis-2019-215386.
4. Kivitz AJ, Nash P, **Tahir H**, Everding A, Mann H, Kaszuba A, Pellet P, Widmer A, Pricop L, Abrams K. Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study. *Rheumatol Ther*. 2019 Sep;6(3):393-407.
5. Mease P, van der Heijde D, Landewé R, Mpofu S, Rahman P, **Tahir H**, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. *Ann Rheum Dis*. 2018 Mar 17.
6. Pavelka K, Kivitz A, Dokoupilova E, Blanco R, Maradiaga M, **Tahir H**, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. *Arthritis Res Ther*. 2017 Dec 22;19(1):285.
7. **Tahir H**, Deodhar A, Genovese M, Takeuchi T, Aelion J, Van den Bosch F, Haemmerle S, Richards HB. Secukinumab in Active Rheumatoid Arthritis after Anti-TNF α Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study. *Rheumatol Ther*. 2017 Dec;4(2):475-488.
8. **Tahir H**, Biro I, Donnelly S, Greenwood M. Randomised, prospective, non-blinded pilot study comparing the effect of intramuscular steroid injections and intralesional steroid injections in the management of tennis elbow. *BMJ Open Sport Exerc Med*. 2017 Feb 10;2(1)
9. Kavanaugh A, Mease PJ, Reimold AM, **Tahir H**, et al. FUTURE-1 Study Group. Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study. *Arthritis Care Res (Hoboken)*. 2017 Mar;69(3):347-355.
10. **Tahir H**. Therapies in ankylosing spondylitis – from clinical trials to clinical practice. *Rheum* 2018 Aug 1;57
11. Mease PJ, Kavanaugh A, Reimold A, **Tahir H**, Rech J et al. Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial. *RMD Open*. 2018 Aug 13;4(2)
12. Wodehouse T, Poply K, Ramaswamy S, Bourke J, **Tahir H** et al. A pilot study investigating whether quantitative sensory testing alters after treatment in patients with fibromyalgia. *Br J Pain*. 2018 Nov;12(4):250-256.
13. Pavelka K, Kivitz A, Dokoupilova E, Blanco R, Maradiaga M, **Tahir H**, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. *Arthritis Res Ther*. 2017 Dec 22;19(1):285.
14. Raine C, Canning B, Marks J, Donnelly S, Ong V, **Tahir H**. Severe gangrene in a patient with anti-RNP positive limited cutaneous systemic sclerosis/rheumatoid arthritis overlap syndrome caused by vasculopathy and vasculitis. *Eur J Rheumatol*. 2018 Dec;5(4):269-271.
15. Biro I, Bubbear J, Donnelly S, Fattah Z, Sarkodieh J, Ranganathan A, **Tahir H**. Teriparatide and vertebral fracture healing in Ankylosing Spondylitis. *Trauma Case Rep*. 2017 Nov 8;12:34-39.

Medico-Legal Work

I have prepared medicolegal reports for medical negligence and personal injury cases since 2005, including complex claims and serious injury reports. Reports are written in line with CPR recommendations, providing carefully written, balanced and independent opinion, while highlighting the possible range of opinion on the matter in question.

I have assessed over 250 personal injury and clinical negligence cases affecting claimants, including those with occupational musculoskeletal disorders, fibromyalgia, inflammatory arthritis (rheumatoid and psoriatic arthritis, ankylosing spondylitis) and lupus, as well as those with spinal pain, and other chronic pain syndromes.

I have prepared reports for both Claimants and Defendants in a ratio of 60:40.

I have been instructed as a Single Joint Expert, Joint expert and am available for court appearances and conferences with counsel in preparation for cases. I have also undertaken urgent reports.

I am a registered member of The National Expert Witness Agency, Premex Plus Panel, and Expert Witness.

Recent Service Achievements

I provide a specialist service for patients with Arthritis, which includes a focus on up to date care and streamline the management of complex patients. I have developed a novel, cost effective weekly QIP MDT virtual biologic clinic, to facilitate patients access to biologics leading to improved standards of care, reducing treatment delays, integrating research and clinical practice and offering excellent training opportunity to maintain specialist knowledge on safe and effective prescribing. Awarded **Barts Health Innovation in health awards runner up in 2018**.

I have led a nationally recognised AS Service (562 patients) recognised by the BSR as an **Emerging Best UK Practice** (2016). NASS regard the unit as a Centre of Excellence resulting in multiple out of region referrals, second opinions and has successfully reduced the time from symptoms to diagnosis to an average of 3.1 years. I co-developed the first Skype AS clinic at WXH and set up a new dedicated physio service for rheumatology patients.

I co-developed a Rheum Ambulatory Clinic providing access to A&E and GPs for urgent rheumatology assessments, I proposed, secured funding and co-designed the MySpA Educational App, available free of charge on both Google play and Apple Store. The App provides instant access to medical information, exercises and assessments, to help patients manage their arthritis.

I continue to engage and develop new patient education material. Following a successful bid for an education grant, at WXH, I introduced 5 I pads in the rheumatology waiting area to support patient education. I co-developed a WXH Quarterly Rheumatology Newsletter updating patients and GPs about the service. I obtained funding and introduced a Virtual Nurse measuring BP and BMI, with the aim of reducing waiting times in Rheumatology clinics.

Research Experience

Following on from my **2 NIHR research recognition awards** in 2016, I continue to be passionate about Clinical Research and am committed to continuing my involvement, despite a busy clinical job with the aim of capturing research, funding and producing publications, and presenting at International meetings.

I was promoted to Honorary Reader status last year in Experimental Medicine and Rheumatology at the William Harvey Research Institute, QMW.

At WXH, as Research lead, I promoted and embedded a research culture within the unit. In the last few years, the unit at WXH participated in a large number of multi-national phase 3/4 national portfolio studies, of which I was the Principal Investigator. I have also been the National Chief investigator for a number of studies.

I have consistently been the lead recruiter nationally. I present the outcomes of a number of the studies at a National (BSR) and International level (ACR, EULAR, PSR, Arab conference).

In the last 2 years I have had 15 publications (3 first author) and over 30 abstracts. I have co-written a Chapter on 'Infections' in the textbook of Sports Medicine. I am the Editor in chief of the FY Journal.

Teaching Activities

I thoroughly enjoy teaching and continue to actively participate in both Undergraduate and Postgraduate teaching. I teach medical students, nursing staff and colleagues, formally and informally, using a variety of teaching styles, seeking feedback to continually improve my teaching skills.

I have hosted 3 diets every year of triple cycles of the MRCP PACES exam at WXH (examining 270 doctors /year), and recently was the first site in the country to run the pilot PACES 2020 exam. I am on the panel of Chairs of International examiners and a board member of the Clinical Exam Board and Scenario Editorial Committee of the MRCP PACES exam. I have been actively involved in the development of the new PACES 2020.

I was an active member the BSR Education and training committee and the BSR e-learning group, reviewing material and lectures which have been presented on the RCP/BSR learning platform at an International level.

Committees

1. BSR SAGWG – involved in critically appraising and reviewing national standards and guidelines in rheumatology and helping implement at a local and regional level and instigate them to my practice with annual review
2. BSR Education and Training Committee (now remitted) - The main achievements have been co-chairing 2 consecutive national rheumatology Autumn Conferences. I was actively involved in the e-learning group, reviewing material and lectures which were presented on the RCP/BSR learning platform at an international level
3. RCP representative for Consultant appointments committee
4. Previous Chair of the national and member of the European steering group for the RA Education programme (InforMD)
5. Member of the MRCP Clinical Exam Board
6. Member of the MRCP PACES Scenario Editorial Committee